Swedish Orphan Biovitrum AB (SOBI) AI Stock Analysis

• Market Cap: kr99.47B
• Dividend Yield: N/A
• Average Volume (3M): 247.21K
• Price to Earnings (P/E): 22.7
• Beta (1Y): 0.98
• Revenue Growth: 13.75%
• EPS Growth: 101.18%
• Country: SE
• Employees: 1,895
• Sector: Healthcare
• Sector Strength: 47
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.83
• Shares Outstanding: 356,000,060
• 10 Day Avg. Volume: 174,019
• 30 Day Avg. Volume: 247,213
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr336.50
• Price Target Upside: 15.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 71 Outperform
• Price Target: kr314.00 ▲(7.31% Upside)

Swedish Orphan Biovitrum AB's strong financial performance, particularly in profitability and balance sheet health, is the primary driver of its stock score. Technical analysis suggests a neutral trend with potential overbought conditions, while valuation metrics indicate moderate pricing. The absence of earnings call and corporate events data limits the analysis to these factors.

Swedish Orphan Biovitrum AB Business Overview & Revenue Model

Company Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

How the Company Makes Money

SOBI generates revenue primarily through the sale of its specialty pharmaceuticals, particularly those developed for rare diseases. The company's key revenue streams include product sales from its proprietary therapies, such as those for hemophilia and immune deficiencies. In addition, SOBI engages in strategic partnerships and collaborations with other pharmaceutical companies, which may include co-development agreements and licensing deals that provide upfront payments, milestone payments, and royalties on future sales. These partnerships enhance SOBI's product pipeline and market reach, contributing significantly to its overall earnings. Furthermore, SOBI's focus on niche markets allows it to maintain pricing power for its innovative therapies.

Swedish Orphan Biovitrum AB Financial Statement Overview

Summary

Swedish Orphan Biovitrum AB shows strong financial health with robust profitability and a solid balance sheet. Revenue and profit margins are improving, but cash flow management needs attention due to a decrease in free cash flow.

Income Statement

Swedish Orphan Biovitrum AB demonstrates strong profitability with a consistent gross profit margin above 77% and a net profit margin improving to over 16% in the TTM. Revenue growth is steady, with a notable increase of 2.79% in the TTM. EBIT and EBITDA margins are robust, indicating efficient operations. However, the slight decline in EBIT margin from previous years suggests potential cost pressures.

Balance Sheet

The company maintains a healthy balance sheet with a declining debt-to-equity ratio, now at 0.33 in the TTM, indicating reduced leverage. Return on equity has improved to 11.25%, showcasing effective use of equity. The equity ratio remains stable, reflecting a solid financial position. However, the decrease in total assets and stockholders' equity over the periods may pose a risk if not managed properly.

Cash Flow

Operating cash flow remains strong, though the free cash flow has decreased by 23.63% in the TTM, which could impact future investments. The operating cash flow to net income ratio is healthy, but the decline in free cash flow to net income ratio suggests potential liquidity challenges. The company needs to address the negative free cash flow growth to maintain financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.50B	26.03B	22.12B	18.79B	15.53B	15.26B
Gross Profit	16.15B	20.24B	17.13B	14.01B	12.04B	12.04B
EBITDA	7.46B	9.30B	7.23B	6.05B	5.71B	6.73B
Net Income	3.50B	3.88B	2.41B	2.64B	2.68B	3.25B
Balance Sheet
Total Assets	68.75B	75.44B	74.03B	52.50B	48.66B	48.28B
Cash, Cash Equivalents and Short-Term Investments	1.06B	1.14B	904.00M	1.36B	1.04B	404.00M
Total Debt	12.81B	16.73B	20.48B	9.10B	10.91B	14.57B
Total Liabilities	29.68B	35.15B	40.16B	25.97B	25.46B	28.08B
Stockholders Equity	39.06B	40.29B	33.87B	26.52B	23.20B	20.21B
Cash Flow
Free Cash Flow	1.78B	4.38B	-473.00M	3.19B	5.10B	1.36B
Operating Cash Flow	4.45B	7.39B	4.47B	4.67B	5.47B	5.21B
Investing Cash Flow	-2.73B	-3.09B	-21.90B	-1.48B	-367.00M	-3.96B
Financing Cash Flow	-1.28B	-4.00B	17.01B	-2.99B	-4.47B	-1.57B

Swedish Orphan Biovitrum AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 292.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Positive. The current price of 292.6 is above the 20-day moving average (MA) of 277.90, above the 50-day MA of 280.27, and below the 200-day MA of 298.13, indicating a neutral trend. The MACD of 2.96 indicates Negative momentum. The RSI at 63.55 is Neutral, neither overbought nor oversold. The STOCH value of 82.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SOBI.

Swedish Orphan Biovitrum AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOBI	71 Outperform	kr99.47B	22.74	11.60%	―	13.75%	101.18%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
ORXOF	―	$73.34M	―	-344.98%	―	―	―
AC6	―	€37.60M	―	-161.07%	―	―	―
6FN	―	€10.02M	―	-191.68%	―	―	―
40M	―	€32.02M	―	-32.52%	―	―	―
ERMA	―	kr179.01M	―		―	―	―

Swedish Orphan Biovitrum AB Corporate Events

Sobi Reports Strong Q2 2025 Growth and Pipeline Progress

Sobi reported a strong second quarter in 2025, with a 22% growth at constant exchange rates, driven by significant increases in haematology and immunology revenues. Key developments include the approval of Gamifant for HLH/MAS in Still’s disease and the submission of NASP for uncontrolled gout in the US. The company’s strategic portfolio saw a 65% growth, highlighting its commitment to rare diseases and strong commercial execution. Despite some challenges with Vonjo, Sobi remains focused on expanding its use and advancing its pipeline, supported by organizational restructuring to enhance support for upcoming launches.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi Board Approves Share Repurchase for Incentive Program

Swedish Orphan Biovitrum AB’s Board of Directors has decided to repurchase class C shares to fulfill commitments under its long-term incentive programs. This move, authorized by the Annual General Meeting, aims to convert these shares into common shares, increasing the total number of common shares held by the company.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi and Apellis Amend Royalty Agreement for Aspaveli

Sobi has entered into a capped royalty purchase agreement with Apellis Pharmaceuticals, significantly reducing its ex-U.S. royalty obligations for Aspaveli in exchange for a $275 million upfront payment and potential milestone payments. This strategic move underscores Sobi’s commitment to advancing treatments for rare diseases, particularly C3G and IC-MPGN, and highlights the potential of Aspaveli to transform patient outcomes in these areas.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi’s Gamifant Receives FDA Approval for Treating MAS in Still’s Disease

Swedish Orphan Biovitrum AB (Sobi) announced the FDA approval of Gamifant (emapalumab-lzsg) as the first treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still’s disease. This approval, based on pivotal studies showing significant patient response, positions Gamifant as a critical therapeutic option, addressing unmet medical needs and potentially improving patient outcomes in this severe condition.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.